NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Genvax Technologies

Genvax Technologies

Private
Ames, IowaHealthcare & Life Scienceshttps://www.genvax.com/

Last Round

Grant

Apr 23, 2025

Total Funding Raised

$12.22M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Genvax Technologies is a biotechnology company that develops self-amplifying mRNA (saRNA) and nanoparticle-based vaccines for the animal health industry.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Application

Keywords

animal healthmRNA vaccineself-amplifying mRNAsaRNAnanoparticle vaccinelivestock vaccineveterinary biotechagtechvaccine platformpredictive analyticsdisease surveillancecustom vaccineherd healthbiotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Genvax Technologies Comparables

Compare Genvax Technologies with similar companies based on industry and business-model similarity.

Genvax Technologies comparables — related companies by embedding similarity
CompanySimilarityMarket Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

Genvax Technologies Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantApr 23, 2025
SeedFeb 3, 2025
Early FundingJun 24, 2024
SeedAug 9, 2022
GrantApr 18, 2022
Pre Seed
Feb 1, 2021

Key People

Founding team and executive leadership

Joel Harris

Chief Executive Officer

Executive Team

Genvax Technologies Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 17, 2026

    Monthly visitors increased 30% MoM.

  • Apr 23, 2025

    $278K grant round completed.

Genvax Technologies Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Genvax Technologies Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Genvax Technologies's valuation, stock price, and market status.

Firmographic Details

HeadquartersAmes, Iowa
Employee Range8
Year Founded2021
Last FundingApr 23, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.